Elanco Animal Health (NYSE:ELAN) Reaches New 1-Year High - Here's What Happened

Key Points

• Elanco Animal Health's stock recently hit a new 52-week high of $20.92, closing at $20.81 with a trading volume of over 7.9 million shares.
• Analyst ratings vary, with Zacks downgrading the stock to "hold," while other firms like Piper Sandler and Stifel Nicolaus have raised their price targets, with an average consensus price target of $18.33.
• In its latest earnings report, Elanco Animal Health reported $0.26 EPS and $1.24 billion in revenue, exceeding analysts' expectations and showing a 4.8% revenue increase year-over-year.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $20.92 and last traded at $20.81, with a volume of 7967362 shares changing hands. The stock had previously closed at $20.14.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ELAN shares. Zacks Research cut shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Piper Sandler increased their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, August 11th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Stifel Nicolaus raised their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a report on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $18.33.

Elanco Animal Health Stock Up 3.3%

The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The company's fifty day moving average is $17.51 and its 200-day moving average is $13.94. The company has a market cap of $10.34 billion, a PE ratio of 24.20, a PEG ratio of 3.74 and a beta of 1.65.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company's revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Allworth Financial LP boosted its stake in shares of Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after acquiring an additional 2,090 shares during the last quarter. NBC Securities Inc. purchased a new position in shares of Elanco Animal Health during the 1st quarter worth $40,000. Parallel Advisors LLC raised its position in shares of Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after purchasing an additional 1,852 shares during the period. Versant Capital Management Inc lifted its stake in shares of Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after buying an additional 1,740 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in shares of Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock valued at $53,000 after buying an additional 2,414 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.